Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCL35B
|
|||
| Drug Name |
Bermekimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hidradenitis suppurativa [ICD-11: ED92.0; ICD-10: L73.2] | Phase 2 | [1] | |
| Company |
JOHNSON & JOHNSON
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03512275) A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa. U.S.National Institutes of Health. | |||
| REF 2 | Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021 Jun;30 Suppl 1:8-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.